AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis

The fixed-dose combination therapy containing the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (G/P) achieved in a Japanese PIII study a sustained virologic response at 12 weeks post treatment (SVR12) and 24 weeks post treatment (SVR24) of 100%...read more